|
ecancermedicalscience：抗真菌药物或可有效治疗癌症
2015年4月17日 讯 /生物谷BIOON/ --近日，一项刊登在国际杂志ecancermedicalscience上的研究论文中，来自ReDO（对药物进行重新定向的肿瘤研究计划）计划小组的研究者通过研究表示，一种常见的抗真菌疗法或可用于治疗癌症。ReDO计划即国际抗癌科学家联合在一起进行的一项大型研究，致力于开发利用常见药物来作为新型的癌症疗法。 该项计划如今已经发表了关于药物开发的数篇研究报道，而且这些药物具有一定的临床证据足以进行临床试验。其中伊曲康唑就是一种用于治疗广谱真菌感染的药物，包括皮肤和指甲的感染等，该药物同时或可作为一种新型的抗癌疗法。Pan Pantziarka指出，伊曲康唑在治疗一系列癌症患者上表现出了巨大潜力，尤其是非小细胞肺癌及某些罕见的恶性肿瘤。 伊曲康唑是一种非专利制剂，其非常廉价而且有证据表明其可以有效抑制前列腺癌的转移，研究者表示，这或许就可以使得伊曲康唑成为极具吸引力的新型癌症药物，不仅对于中低收入国家非常重要，而且对于卫生系统不堪重负的国家也是一项福利。但在抗真菌药物进入抗癌市场前却难免会遇到一些障碍，目前研究者正在收集对药物重新定向的数据，旨在得到医学界的关注。 这些重新定向的抗癌药物，比如抗真菌药物或止痛药或许都可以应用于未来的癌症药物开发研究过程，研究者希望提高科学家对重新定向药物的认知来使得更多抗癌药物被发现。 PMC: Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent Pan Pantziarka1,2, Vidula Sukhatme3, Gauthier Bouche1, Lydie Meheus1 and Vikas P Sukhatme3,4
Itraconazole, a common triazole anti-fungal drug in widespread clinical use, has evidence of clinical activity that is of interest in oncology. There is evidence that at the clinically relevant doses, itraconazole has potent anti-angiogenic activity, and that it can inhibit the Hedgehog signalling pathway and may also induce autophagic growth arrest. The evidence for these anticancer effects, in vitro, in vivo, and clinical are summarised, and the putative mechanisms of their action outlined. Clinical trials have shown that patients with prostate, lung, and basal cell carcinoma have benefited from treatment with itraconazole, and there are additional reports of activity in leukaemia, ovarian, breast, and pancreatic cancers. Given the evidence presented, a case is made that itraconazole warrants further clinical investigation as an anti- cancer agent. Additionally, based on the properties summarised previously, it is proposed that itraconazole may synergise with a range of other drugs to enhance the anti-cancer effect, and some of these possible combinations are presented in the supplementary materials accompanying this paper. |
